1 |
CYSLTR1
| 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction | D00529
D00529
|
Montelukast
| 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
2 |
CYSLTR1
| 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction | D08229
D08229
|
Montelukast
| 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
3 |
CHRM1
| 8件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D01000
D01000
|
Bethanechol
| 1件: 98 98 |
4 |
CHRM2
| 6件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton | D01000
D01000
|
Bethanechol
| 1件: 98 98 |
5 |
CHRM3
| 11件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D01000
D01000
|
Bethanechol
| 1件: 98 98 |
6 |
CHRM4
| 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton | D01000
D01000
|
Bethanechol
| 1件: 98 98 |
7 |
CHRM5
| 6件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases | D01000
D01000
|
Bethanechol
| 1件: 98 98 |
8 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00357
D00357
|
Losartan
| 18件: 17 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
9 |
AGTR1
| 16件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D08146
D08146
|
Losartan
| 18件: 17 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
10 |
S1PR1
| 3件: FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| 3件: 96 96, 97, 98 |
11 |
S1PR3
| 2件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| 3件: 96 96, 97, 98 |
12 |
FCER1A
| 4件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Phospholipase D signaling pathway, Fc epsilon RI signaling pathway, Asthma | D05251
D05251
|
Omalizumab
| 7件: 46 46, 53, 65, 98, 162, 226, 299 |
13 |
MTOR
| 51件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy | D00753
D00753
|
Sirolimus
| 41件: 2 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
14 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
15 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
16 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
17 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
18 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
19 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
20 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
21 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
22 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
23 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
24 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
25 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
26 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
27 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
28 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
29 |
SIGLEC8
| - | D11906
D11906
|
Lirentelimab
| 1件: 98 98 |
30 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00088
D00088
|
Hydrocortisone
| 2件: 98 98, 299 |
31 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00246
D00246
|
Budesonide
| 3件: 98 98, 228, 299 |
32 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00689
D00689
|
Beclomethasone dipropionate
| 1件: 98 98 |
33 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00690
D00690
|
Mometasone
| 2件: 98 98, 162 |
34 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00690
D00690
|
Mometasone furoate
| 2件: 98 98, 162 |
35 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01708
D01708
|
Fluticasone propionate
| 2件: 98 98, 228 |
36 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03325
D03325
|
Mometasone
| 2件: 98 98, 162 |
37 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D07495
D07495
|
Beclomethasone dipropionate
| 1件: 98 98 |
38 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D07981
D07981
|
Fluticasone
| 3件: 98 98, 228, 299 |
39 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D08227
D08227
|
Mometasone
| 2件: 98 98, 162 |
40 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D00364
D00364
|
Loratadine
| 4件: 13 13, 46, 89, 98 |
41 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D01172
D01172
|
Diphenylpyraline
| 1件: 98 98 |
42 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D01627
D01627
|
Diphenylpyraline
| 1件: 98 98 |
43 |
HRH1
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels | D07862
D07862
|
Diphenylpyraline
| 1件: 98 98 |
44 |
HRH2
| 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion | D00318
D00318
|
Famotidine
| 7件: 6 6, 46, 61, 86, 98, 107, 300 |
45 |
IL4R
| 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | D10354
D10354
|
Dupilumab
| 4件: 51 51, 98, 160, 162 |
46 |
IL5
| 13件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | D04923
D04923
|
Mepolizumab
| 4件: 44 44, 45, 98, 162 |
47 |
IL5
| 13件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | D08985
D08985
|
Reslizumab
| 2件: 44 44, 98 |
48 |
IL5RA
| 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | D09874
D09874
|
Benralizumab
| 5件: 44 44, 45, 98, 162, 299 |
49 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00355
D00355
|
Lansoprazole
| 7件: 63 63, 71, 85, 98, 166, 222, 299 |
50 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
51 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01207
D01207
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
52 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01984
D01984
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
53 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D04056
D04056
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
54 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05259
D05259
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
55 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05261
D05261
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
56 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
57 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D08903
D08903
|
Dexlansoprazole
| 1件: 98 98 |
58 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D09339
D09339
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
59 |
ATP4A
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D11784
D11784
|
Vonoprazan
| 2件: 63 63, 98 |
60 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00355
D00355
|
Lansoprazole
| 7件: 63 63, 71, 85, 98, 166, 222, 299 |
61 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D00455
D00455
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
62 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01207
D01207
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
63 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D01984
D01984
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
64 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D04056
D04056
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
65 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05259
D05259
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
66 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D05261
D05261
|
Omeprazole
| 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
67 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D07917
D07917
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
68 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D08903
D08903
|
Dexlansoprazole
| 1件: 98 98 |
69 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D09339
D09339
|
Esomeprazole
| 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
70 |
ATP4B
| 4件: Oxidative phosphorylation Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion | D11784
D11784
|
Vonoprazan
| 2件: 63 63, 98 |
71 |
S1PR5
| 2件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| 3件: 96 96, 97, 98 |
72 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| 10件: 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
73 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D00822
D00822
|
Citalopram
| 7件: 6 6, 8, 13, 18, 46, 98, 127 |
74 |
SLC6A4
| 2件: Synaptic vesicle cycle Synaptic vesicle cycle, Serotonergic synapse | D07704
D07704
|
Citalopram
| 7件: 6 6, 8, 13, 18, 46, 98, 127 |
75 |
TNF
| 67件: Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
76 |
VDR
| 5件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188
D00188
|
Cholecalciferol
| 25件: 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
77 |
S1PR4
| 3件: FoxO signaling pathway FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| 3件: 96 96, 97, 98 |
78 |
S1PR2
| 2件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D10930
D10930
|
Etrasimod
| 3件: 96 96, 97, 98 |